A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra [lopinavir/ritonavir] and Viread [tenofovir] in Antiretroviral Naive Patients

Trial Profile

A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra [lopinavir/ritonavir] and Viread [tenofovir] in Antiretroviral Naive Patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top